Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Adaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation (ADPT) Stock Ticker

NASDAQ: ADPT · Healthcare · Biotechnology
$29.43-0.47%
USD · as of 2026-09-28 · market cap $4.7B
Open ADPT in TickrDownload for iPhone

ADPT right now

Trading at the top of its 52-week range.
bullishBreaking out: New 52-week high with a golden cross
Tickr signals on ADPT
Breaking outNew 52-week high with a golden cross
Options expect by Oct 6±9.3%
Options expect by Oct 29±19.3%
Priced in for Nov 4 earnings±21.2%
IV rank (30-day)14% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full ADPT picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on ADPT
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

ADPT stock facts

Ticker symbolADPT
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$4.7B
CEOChad Robins
Employees624
HeadquartersSeattle, WA, US
IPO date2019-06-27
Websitewww.adaptivebiotech.com

What you can see for ADPT on Tickr

Live ADPT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ADPT report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Adaptive Biotechnologies Corporation?

The ticker symbol for Adaptive Biotechnologies Corporation is ADPT, listed on the NASDAQ Global Select.

What is ADPT?

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers…

HomeExploreMarketLists
All pages